These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 38133871

  • 1. Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma.
    Zhou KI, Hanks BA, Strickler JH.
    J Gastrointest Cancer; 2024 Jun; 55(2):483-496. PubMed ID: 38133871
    [Abstract] [Full Text] [Related]

  • 2. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma.
    van Velzen MJM, Derks S, van Grieken NCT, Haj Mohammad N, van Laarhoven HWM.
    Cancer Treat Rev; 2020 Jun; 86():102024. PubMed ID: 32388292
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
    Haag GM, Czink E, Ahadova A, Schmidt T, Sisic L, Blank S, Heger U, Apostolidis L, Berger AK, Springfeld C, Lasitschka F, Jäger D, von Knebel Doeberitz M, Kloor M.
    Int J Cancer; 2019 Apr 01; 144(7):1697-1703. PubMed ID: 30499151
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
    Kundel Y, Sternschuss M, Moore A, Perl G, Brenner B, Goldvaser H.
    Cancer Med; 2020 Oct 01; 9(20):7613-7625. PubMed ID: 32869544
    [Abstract] [Full Text] [Related]

  • 5. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
    Weinberg BA, Xiu J, Hwang JJ, Shields AF, Salem ME, Marshall JL.
    Oncologist; 2018 Oct 01; 23(10):1171-1177. PubMed ID: 29703766
    [Abstract] [Full Text] [Related]

  • 6. MSI Analysis in Solid and Liquid Biopsies of Gastroesophageal Adenocarcinoma Patients: A Molecular Approach.
    Boldrin E, Piano MA, Alfieri R, Mazza M, Vassallo L, Scapinello A, Pilati P, Curtarello M.
    Int J Mol Sci; 2021 Jul 06; 22(14):. PubMed ID: 34298864
    [Abstract] [Full Text] [Related]

  • 7. Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
    Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Randon G, Kook MC, An JY, Grabsch HI, Prisciandaro M, Nichetti F, Noh SH, Sohn TS, Kim S, Wotherspoon A, Morano F, Cunningham D, Lee J, Cheong JH, Smyth EC, Pietrantonio F.
    Eur J Cancer; 2024 May 06; 203():114043. PubMed ID: 38598921
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
    Fei S, Lu Y, Chen J, Qi J, Wu W, Wang B, Han Y, Wang K, Han X, Zhou H, Wang J, Chen J.
    Chemotherapy; 2023 May 06; 68(4):197-209. PubMed ID: 37331333
    [Abstract] [Full Text] [Related]

  • 9. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
    Lin EM, Gong J, Klempner SJ, Chao J.
    World J Gastroenterol; 2018 Jul 07; 24(25):2686-2697. PubMed ID: 29991874
    [Abstract] [Full Text] [Related]

  • 10. Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses.
    Imamura Y, Toihata T, Haraguchi I, Ogata Y, Takamatsu M, Kuchiba A, Tanaka N, Gotoh O, Mori S, Nakashima Y, Oki E, Mori M, Oda Y, Taguchi K, Yamamoto M, Morita M, Yoshida N, Baba H, Mine S, Nunobe S, Sano T, Noda T, Watanabe M.
    Int J Cancer; 2021 Mar 01; 148(5):1260-1275. PubMed ID: 32997798
    [Abstract] [Full Text] [Related]

  • 11. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
    Maron SB, Chase LM, Lomnicki S, Kochanny S, Moore KL, Joshi SS, Landron S, Johnson J, Kiedrowski LA, Nagy RJ, Lanman RB, Kim ST, Lee J, Catenacci DVT.
    Clin Cancer Res; 2019 Dec 01; 25(23):7098-7112. PubMed ID: 31427281
    [Abstract] [Full Text] [Related]

  • 12. [Clinical significance of combined therapy with immune checkpoint inhibitor in perioperative treatment for locally advanced gastric cancer or adenocarcinoma of gastroesophageal junction].
    Zhu ZG.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul 25; 27(7):659-665. PubMed ID: 39004980
    [Abstract] [Full Text] [Related]

  • 13. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
    Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, Tan C, Wang Y, Catenacci DVT.
    Clin Cancer Res; 2020 Dec 15; 26(24):6453-6463. PubMed ID: 32820017
    [Abstract] [Full Text] [Related]

  • 14. ASO Author Reflections: Neoadjuvant Chemotherapy Combined with Immunotherapy is a Promising Strategy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
    Sun X, Lyu J, Yin Y, Tao K.
    Ann Surg Oncol; 2024 Nov 15; 31(12):8179-8180. PubMed ID: 39212861
    [No Abstract] [Full Text] [Related]

  • 15. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio T, Desrame J, Lièvre A, Garcia-Larnicol ML, Pudlarz T, Cohen R, Memmi S, Vernerey D, Henriques J, Lefevre JH, Svrcek M.
    J Clin Oncol; 2023 Jan 10; 41(2):255-265. PubMed ID: 35969830
    [Abstract] [Full Text] [Related]

  • 16. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
    Nappo F, Fornaro L, Pompella L, Catanese S, Lavacchi D, Spallanzani A, Cappetta A, Puzzoni M, Murgioni S, Barsotti G, Tirino G, Pellino A, Vivaldi C, Strippoli A, Aprile G, Di Donato S, Mazza E, Prisciandaro M, Antonuzzo L, Zagonel V, Cascinu S, De Vita F, Lonardi S.
    J Cancer Res Clin Oncol; 2023 Aug 10; 149(9):6601-6611. PubMed ID: 36795195
    [Abstract] [Full Text] [Related]

  • 17. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Moehler M, Högner A, Wagner AD, Obermannova R, Alsina M, Thuss-Patience P, van Laarhoven H, Smyth E.
    Eur J Cancer; 2022 Nov 10; 176():13-29. PubMed ID: 36183651
    [Abstract] [Full Text] [Related]

  • 18. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
    Koemans WJ, Chalabi M, van Sandick JW, van Dieren JM, Kodach LL.
    Cancer Lett; 2019 Feb 01; 442():279-286. PubMed ID: 30419350
    [Abstract] [Full Text] [Related]

  • 19. Recent Incidence Trend of Surgically Resected Esophagogastric Junction Adenocarcinoma and Microsatellite Instability Status in Japanese Patients.
    Imamura Y, Watanabe M, Toihata T, Takamatsu M, Kawachi H, Haraguchi I, Ogata Y, Yoshida N, Saeki H, Oki E, Taguchi K, Yamamoto M, Morita M, Mine S, Hiki N, Baba H, Sano T.
    Digestion; 2019 Feb 01; 99(1):6-13. PubMed ID: 30554205
    [Abstract] [Full Text] [Related]

  • 20. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
    Yoshida T, Ogura G, Tanabe M, Hayashi T, Ohbayashi C, Azuma M, Kunisaki C, Akazawa Y, Ozawa S, Matsumoto S, Suzuki T, Mitoro A, Fukunaga T, Shimizu A, Fujimoto G, Yao T.
    Cancer Biol Ther; 2022 Dec 31; 23(1):191-200. PubMed ID: 35220884
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.